机译:Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open‐label, multicenter phase 4 trial
Department of Nephrology,Transplantation, Dialysis and Apheresis;
Department of Nephrology and Organ Transplantation,CHU Toulouse;
Department of Nephrology, Transplantation and Clinical Immunology of Edouard Herriot HospitalDepartment of Nephrology,Transplantation, Dialysis, CHU CaenDepartment of Nephrology and Transplantation,CHU StrasbourgLaboratory of Virology,CHU BordeauxDepartment of Nephrology and Kidney Transplantation, Necker Hospital,Assistance Publique‐H?pitauxDepartment of Nephrology and Transplantation,CHU LimogesDepartment of Nephrology and Transplantation,Brest University HospitalDepartment of Nephrology and Kidney Transplantation, INSERM 1186, Henri Mondor Hospital, AssistanceCHU Bordeaux,Service d’information médicaleUMR 5164‐ImmunoConcEpT,University of Bordeaux;
clinical research; clinical trial; immunosuppressant ‐ mechanistic target of rapamycin: everolimus; infection and infectious agents ‐ viral: Cytomegalovirus (CMV); kidney transplantation; nephrology; practice; T cell biology;